AstraZeneca's Hopes Still High For Tozorakimab In COPD

The company's IL-33 drug failed to improve breathing in a chronic obstructive pulmonary disease Phase II trial but benefited patients who had suffered moderate or severe exacerbations in the previous year.

Sodertalje, Sweden - April 27, 2014: Three purple flags with the logo for Atrazeneca flying in the wind on top of the flagpoles against the blue sky.

AstraZeneca PLC's tozorakimab may have missed its primary goal in a mid-stage trial but the UK major remains confident that the IL-33 monoclonal antibody is a potential best-in-class candidate for chronic obstructive pulmonary disease (COPD).

More from Respiratory

More from Therapy Areas